A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

February 7, 2015

Primary Completion Date

September 15, 2016

Study Completion Date

September 15, 2016

Conditions
Parkinson's Disease
Interventions
DRUG

TVP-1012

TVP-1012 1mg Tablets

DRUG

Placebo

Placebo tablets

Trial Locations (55)

Unknown

Nagoya

Matsuyama

Touon

Kitakyushu

Onoshiro

Asahikawa

Iwamizawa

Akashi

Kobe

Tsuchiura

Tsukuba

Morioka

Takamatsu

Fujisawa

Sagamihara

Yokohama

Gōshi

Sendai

Matsumoto

Higashisonogi-gun

Nishisonogi-gun

Tenri

Jouetsu

Higashiosaka

Suita

Takatsuki

Toyonaka

Irima-gun

Fuji

Hamamatsu

Izunokuni

Shimono

Yoshinogawa

Bunkyo-ku

Fuchū

Kodaira

Meguro-ku

Nerima-ku

Ōta-ku

Setagaya-ku

Shibuya-ku

Akita

Aomori

Fukuoka

Fukushima

Hiroshima

Kochi

Kyoto

Niigata

Okayama

Osaka

Tokushima

Toyama

Wakayama

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY